Truncated SLC30A8 Protein Enhances Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current models of type 2 diabetes in mice do not fully replicate the human protective phenotype against type 2 diabetes, particularly in relation to SLC30A8 mutations, and fail to demonstrate enhanced insulin secretion capacity.
Innovation Solution
Generation of a mouse model with a mutated Slc30a8 locus that encodes a truncated SLC30A8 protein, leading to increased insulin secretion capacity, particularly in response to hyperglycemia and high-fat diets, without significant beta-cell proliferation or mass increase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Slc30a8 knockout is performed in mice to study human protective phenotype, then the model should replicate human protection against type 2 diabetes, but the mice exhibit reduced plasma insulin levels and impaired glucose tolerance instead
Solution Approach 1:
The patent applies parameter changes by modifying the Slc30a8 gene to create a premature stop codon at position 137, resulting in a truncated protein with 136 amino acids. This specific parameter change in the protein structure (truncation at position 136) fundamentally alters the physiological outcome, converting the harmful complete knockout effect into a beneficial protective phenotype that mimics human heterozygous loss-of-function mutations.
2Reliability
If complete Slc30a8 knockout is performed, then the model should show protection against type 2 diabetes, but insulin secretion capacity is reduced
Solution Approach 1:
The patent applies partial action by creating a heterozygous knockout model where only one allele of the Slc30a8 gene is disrupted. This partial knockout (50% reduction in functional protein) is sufficient to confer protection against type 2 diabetes while maintaining adequate insulin secretion capacity, unlike complete knockout which causes severe physiological defects.
3Reliability
If Slc30a8 mutation is introduced to enhance insulin secretion, then protection against type 2 diabetes should be achieved, but beta-cell mass may increase
Solution Approach 1:
The patent substitutes the mechanical approach of increasing beta-cell mass (hyperplasia) with a molecular mechanism approach. The truncated SLC30A8 protein (136 amino acids) acts as a dominant-negative or protective variant that enhances insulin secretion through altered zinc transport or beta-cell survival mechanisms, rather than simply increasing the number of beta cells through proliferation.
Data Source
Figure 1A~1D
Figure 2A~2K
Figure 2L~2P
AI summary
Non-human animal genomes, non-human animal cells, and non-human animals comprising a mutated Slc30a8 locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. The non-human animals can have increased insulin secretory capacity.